# CVS Health Corporation – Consensus ‘buy’ rating and 14.2% Upside Potential

- Link: https://www.directorstalkinterviews.com/cvs-health-corporation-consensus-buy-rating-and-14.2-upside-potential-2/4121179865
- Published: 2024-12-03T13:03:04+00:00
- Author: Charlotte Edwards

**CVS Health Corporation** which can be found using ticker (CVS) have now 25 market
analysts covering the stock. The analyst consensus now points to a rating of ‘buy’.
The target price High/Low ranges between $93.00 and $57.00 with the average target
price sitting at $68.35. Now with the previous closing price of $59.85 this now 
indicates there is a potential upside of 14.2%. There is a 50 day moving average
of $59.32 and the 200 day MA is $62.52. The market cap for the company is 74.35B.
The price for the stock stands currently at: $59.08 USD

 The potential market cap would be $84,902,752,977 based on the market consensus.

The company is not paying dividends at this time.

Other points of data to note are a P/E ratio of 14.99, revenue per share of $290.20
and a 2.37% return on assets.

CVS Health Corporation, together with its subsidiaries, is a diversified health 
solutions company. The Company’s segments include Health Care Benefits, Health Services,
Pharmacy & Consumer Wellness and Corporate/Other. Its Health Care Benefits offer
a range of traditional, voluntary and consumer-directed health insurance products
and related services, including medical, pharmacy, dental and behavioral health 
plans, medical management capabilities, Medicare Advantage and Medicare supplement
plans, and Medicaid health care management services. Its Health Services provides
a full range of pharmacy benefit management solutions, delivers health care services
in its medical clinics, virtually, and in the home, and offers provider enablement
solutions. The Pharmacy & Consumer Wellness segment dispenses prescriptions in its
retail pharmacies and through its infusion operations, provides ancillary pharmacy
services including pharmacy patient care programs, and diagnostic testing.

Share on:
